Clinical Trial

Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

Study acronym: Re-EMBARC
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-05-26; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2023-09-05
Trial Details
NCT Number NCT05892744
Lead Sponsor University of Texas at Austin
Collaborators: Lehigh University
Conditions Major Depressive Disorder, Chronic Major Depression, Recurrent
Enrollment 50 participants
Start Date 2023-09-30
Primary Completion 2027-07-15 (estimated)
Study Completion 2027-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-01